Lomitapide has demonstrated reductions in which lipid parameters?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Lomitapide has demonstrated reductions in which lipid parameters?

Lomitapide lowers the production of apoB-containing lipoproteins by inhibiting microsomal triglyceride transfer protein, which is needed to assemble VLDL in the liver and chylomicrons in the intestine. With fewer VLDL and chylomicrons being secreted, the downstream lipids in the blood drop: LDL-C falls because LDL comes from VLDL, total cholesterol decreases, and triglycerides decrease as well. HDL-C is not a primary target and is not consistently reduced, so the most consistent and clinically meaningful reductions are in total cholesterol, LDL-C, and triglycerides.

Lomitapide lowers the production of apoB-containing lipoproteins by inhibiting microsomal triglyceride transfer protein, which is needed to assemble VLDL in the liver and chylomicrons in the intestine. With fewer VLDL and chylomicrons being secreted, the downstream lipids in the blood drop: LDL-C falls because LDL comes from VLDL, total cholesterol decreases, and triglycerides decrease as well. HDL-C is not a primary target and is not consistently reduced, so the most consistent and clinically meaningful reductions are in total cholesterol, LDL-C, and triglycerides.

More practice questions